About the Symposium

CSIR-IMTECH focuses on cutting edge microbial science and technological research with an aim to deliver new drugs and healthcare solutions for the poorest of poor. For the same, CSIR-IMTECH is intended to enter into collaboration with global pharma giant Johnson & Johnson for development of new drugs for Tuberculosis (TB). In this regard, a Memorandum of Understanding (MoU) would be signed with Johnson & Johnson to further boost research alliance.

CSIR-IMTECH is organizing a one day 'Dr Paul Janssen TB Symposium ' on 17th August 2017. The aim of this symposium is to brainstorm on issues related to TB drug development & public policy. This symposium endeavours to reinforce the vision laid out by late Dr. Paul Janssen who dedicated his life for creating medicines that benefitted millions of patients across the globe.

This symposium will be graced by Dr Paul Stoffels, Chief Scientific Officer of healthcare giant Johnson & Johnson and will also include key government policy makers including leaders from Ministry of Science and Technology to discuss the future research agenda around TB in India.

About Dr. Paul Janssen:

Dr. Paul Janssen was the world's most prolific discoverer of new medicines, some of which are in WHO essential medicines list. The loss of his four year old sister due to Tuberculosis meningitis drove him to pursue a career in medicine. He changed the course of drug development in the 20th century. Dr. Paul was the holder of more than 100 patents. One of his last dreams, to find medicine to treat MDR-TB was realized by Janssen with the first new treatment for Tuberculosis in more than 40 years.